Patients with early- versus late-onset epilepsy exhibited distinct differences in the origin of memory deficits, supporting the practice of subtyping patients by clinical characteristics to identify individualized predictors of cognitive dysfunction, according to the results of a new study.
Opioid analgesics are among the most often prescribed drug classes in the United States. The National Institute on Drug Abuse estimated that in 2014, US pharmacies dispensed 245 million prescriptions for opioids for the treatment of patients with acute or chronic pain.
The Alzheimer’s Prevention Clinic, a specialized program that focuses on the latest treatments for patients with Alzheimer’s disease and state-of-the-art prevention strategies, is helping to reduce the risks associated with the disease. With an emphasis on nutritional approaches, patients at the program receive a personalized plan based on risk factors, genes, medical conditions, and the latest scientific research.
In a series of debates at the 2016 American Academy of Neurology annual meeting, expert physicians debated current and controversial issues in neuroscience. David S. Knopman, MD, FAAN, Professor of Neurology, Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN, advocated for the benefits of cognitive-enhancing activities; Kaycee M. Sink, MD, MAS, Medical Director, Kulynych Memory Assessment Clinic, Wake Forest Baptist Medical Center, Winston-Salem, NC, contended that there is a lack of controlled studies to guide clinical recommendations.
A phase 2 clinical trial of the investigational agent idalopirdine (Lu AE5854), a selective 5-HT6 receptor antagonist, as adjunctive treatment to the cholinesterase inhibitor donepezil has demonstrated improved cognition in patients with mild-to-moderate Alzheimer’s disease. The results also showed a trend toward ameliorating declines in function and global clinical status, researchers reported at the 2016 American Academy of Neurology annual meeting.
The so-called superutilizers among patients with schizophrenia in the Medicaid population had substantially more medical and psychiatric comorbidities and higher rates of emergency department and inpatient resource use than nonsuperutilizers, according to a study based on a large administrative claims database.
Recent advances in brain–computer interfaces have moved these devices closer than ever to daily use, offering hope to millions of patients suffering from neurologic disability, said Karunesh Ganguly, MD, PhD, Assistant Professor of Neurology, University of California, San Francisco, at the 2016 American Academy of Neurology annual meeting.
“Of course, the Holy Grail of pain treatment would be to treat the affected site directly,” said Max M. Klein, PhD, Instructor of Neurology, Massachusetts General Hospital, Boston, at the 2016 American Academy of Pain Medicine meeting.
An often overlooked condition, central neuropathic pain ensues directly when any type of central nervous system (CNS) lesion causes the dysfunction of somatosensory CNS pathways. It occurs most often after a stroke or as sequelae of multiple sclerosis or spinal cord injury, explained James C. Watson, MD, Associate Professor of Neurology, Mayo Clinic, Rochester, MN, at the 2016 American Academy of Pain Medicine meeting. Central neuropathic pain is challenging to diagnose and treat.
Results of a recent study have shown that simvastatin (Zocor) plus vitamin D is effective for the prevention of headache in adults with episodic migraine.
Page 1 of 2
Results 1 - 10 of 18
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology